Monthly Archives

January 2022

Blackhawk’s MindBio Therapeutics to Develop Psychedelic Medicine in Microdoses Ready for Commercial Use to Treat Major Depressive Disorder

Vancouver, British Columbia – TheNewswire – January 17, 2021 – Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (OTC:BLRZF) (Frankfurt:0JJ) (the “Corporation” or “Blackhawk”) is pleased to announce that its wholly-owned subsidiary MindBio Therapeutics Pty Ltd (“MindBio”) is developing a new microdosing formula using LSD (Lysergic Acid Diethylamide) to treat Major Depressive Disorder (“MDD”).     MindBio aims to develop psychedelic microdosing formulations…

Read More

Blackhawk’s TERP Wholesale LLC Receives State-Issued Micro-Business License Allowing for Retail Delivery

Vancouver, British Columbia – TheNewswire – January 12, 2022 – Blackhawk Growth Corp. (the “Company”) (CSE:BLR) (CNSX:BLR.CN) (Frankfurt:0JJ) is pleased to announce that its wholly-owned subsidiary, TERP Wholesale, LLC (“TERP”) has received its California State-issued micro-business license. In addition to allowing TERP to operate as a non-storefront retail delivery dispensary, this license provides strategic opportunities to expand in additional verticals…

Read More

Blackhawk’s TERP Wholesale LLC Reports Unaudited $2,503,133 in Gross Revenue for Nine Months Ended September 30th, 2021

  Vancouver, British Columbia – TheNewswire – January 6, 2022 – Blackhawk Growth Corp. (the “Company”) (CSE:BLR) (CNSX:BLR.CN) (Frankfurt:0JJ) is pleased to provide an update on the operations of its wholly owned subsidiary, TERP Wholesale, LLC (“TERP”). The acquisition of TERP was successfully completed on December 1, 2021.     For the nine months ended September 30, 2021, TERP reported…

Read More

Blackhawk’s MindBio Therapeutics to Develop Proprietary Drug Delivery Technology for Psychedelic Medicines

Vancouver, British Columbia – TheNewswire – January 04, 2022 – Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (OTC:BLRZF) (Frankfurt:0JJ) (the “Corporation” or “Blackhawk”), is pleased to announce that its wholly owned subsidiary, MindBio Therapeutics Pty Ltd (“MindBio”), is developing a proprietary technology and a new scientific method to objectively test the effectiveness and delivery of microdosing psychedelic medicines.   MindBio is currently…

Read More